JP2023548406A - 固形がんを処置するための組成物および方法 - Google Patents

固形がんを処置するための組成物および方法 Download PDF

Info

Publication number
JP2023548406A
JP2023548406A JP2023527693A JP2023527693A JP2023548406A JP 2023548406 A JP2023548406 A JP 2023548406A JP 2023527693 A JP2023527693 A JP 2023527693A JP 2023527693 A JP2023527693 A JP 2023527693A JP 2023548406 A JP2023548406 A JP 2023548406A
Authority
JP
Japan
Prior art keywords
cancer
peroxide
haloperoxidase
composition
oxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548406A5 (https=
Inventor
ロバート シー． アレン，
ジャクソン ティー． ジュニア スティーブンス，
Original Assignee
エクソゼミス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクソゼミス，インコーポレイテッド filed Critical エクソゼミス，インコーポレイテッド
Publication of JP2023548406A publication Critical patent/JP2023548406A/ja
Publication of JP2023548406A5 publication Critical patent/JP2023548406A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/0101—Chloride peroxidase (1.11.1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023527693A 2020-11-11 2021-10-01 固形がんを処置するための組成物および方法 Pending JP2023548406A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112447P 2020-11-11 2020-11-11
US63/112,447 2020-11-11
PCT/US2021/053155 WO2022103515A1 (en) 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer

Publications (2)

Publication Number Publication Date
JP2023548406A true JP2023548406A (ja) 2023-11-16
JP2023548406A5 JP2023548406A5 (https=) 2024-09-24

Family

ID=81601629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527693A Pending JP2023548406A (ja) 2020-11-11 2021-10-01 固形がんを処置するための組成物および方法

Country Status (10)

Country Link
US (1) US20230398190A1 (https=)
EP (1) EP4243835A4 (https=)
JP (1) JP2023548406A (https=)
KR (1) KR20230106646A (https=)
CN (1) CN116710121A (https=)
AU (1) AU2021379542A1 (https=)
CA (1) CA3196357A1 (https=)
IL (1) IL302683A (https=)
MX (1) MX2023005171A (https=)
WO (1) WO2022103515A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250332226A1 (en) * 2022-04-13 2025-10-30 Exoxemis, Inc. Compositions and methods for treating solid cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
EP4548978A3 (en) * 2015-01-29 2025-08-06 Oxyrase, Inc. Methods for inhibiting tumor growth
US10213448B2 (en) * 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US20190271703A1 (en) * 2016-10-26 2019-09-05 Duke University Biomarkers and treatments for metastatic cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL. IMMUNOTHER., vol. 61, JPN6025041133, 2012, pages 1527 - 1534, ISSN: 0005700881 *
J. EXP. MED., vol. 155, JPN6025041132, 1982, pages 1291 - 1308, ISSN: 0005700880 *
J. IMMUNOL., vol. 124, JPN6025041134, 1980, pages 1949 - 1953, ISSN: 0005700879 *

Also Published As

Publication number Publication date
US20230398190A1 (en) 2023-12-14
WO2022103515A1 (en) 2022-05-19
KR20230106646A (ko) 2023-07-13
CA3196357A1 (en) 2022-05-19
EP4243835A1 (en) 2023-09-20
AU2021379542A1 (en) 2023-06-08
IL302683A (en) 2023-07-01
AU2021379542A9 (en) 2024-09-05
MX2023005171A (es) 2023-06-26
EP4243835A4 (en) 2024-08-28
CN116710121A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
CA2720280C (en) Annexin a5 for reducing scar formation in wound healing
KR20080108996A (ko) 셀룰라이트 치료용 아교질분해효소
JP2010148509A (ja) アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法
US20100178273A1 (en) Methods and compositions for treating mucositis
CZ2003848A3 (cs) Způsob léčby poruch spojených s bcl-2 za použití antisense oligomerů bcl-2
Teicher et al. Transforming growth factor-β in in vivo resistance
JP2010511039A (ja) 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
JP2023548406A (ja) 固形がんを処置するための組成物および方法
EP3442564B1 (en) Composition of proenzymes for cancer treatment
JP3980088B2 (ja) 傷治癒を改善するプラスミノーゲン活性化因子からなる製剤の使用
HU215160B (hu) Eljárás humán Cu/Zn szuperoxid dizmutáz előállítására és tisztítására
JP5560491B2 (ja) ケロイド及び肥厚性瘢痕根治治療剤
US5756091A (en) Method of treating tumour cells using catalase
KR20250004257A (ko) 고형 암을 치료하기 위한 조성물 및 방법
WO2019099559A1 (en) Nuclear-targeted dna repair enzymes and methods of use
HK40098212A (zh) 用於治疗实体癌的组合物和方法
JP2009509532A (ja) コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
JP2006505290A (ja) 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
JP2005535674A (ja) 線維症および瘢痕形成の治療におけるコンバターゼインヒビターの使用
WO2009149201A1 (en) Methods of treatment for pulmonary fibrosis
CN102485272A (zh) 重组人Prx-6蛋白在治疗烧烫伤方面的用途
CN100484575C (zh) 一类封闭myc细胞增殖途径的染色质肽药物分子
US9066937B2 (en) Lipoxygenase and its use in wound healing
CN115721603B (zh) 用于非小细胞肺癌术后管理的载药水凝胶及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114